TBC1D21: A Potential Drug Target for Various Diseases (G161514)

Target Name: TBC1D21

NCBI ID: G161514

TBC1D21

TBC1D21: A Potential Drug Target for Various Diseases

TBC1D21, also known as TBC1D21 RAB-GAP, is a gene that encodes a protein belonging to the TBC1 domain family. TBC1 domains are involved in the regulation of cellular processes, including vesicle trafficking and signal transduction. TBC1D21 has gained attention as a potential drug target or biomarker due to its association with several diseases. In this article, we will delve into the various implications of TBC1D21 in different pathological conditions.

The Role of TBC1D21 in Cancer Progression

Cancer is a complex disease characterized by uncontrolled cell growth and invasion. TBC1D21 has been identified as a potential target for cancer therapy due to its involvement in tumor development. Studies have shown that TBC1D21 is upregulated in various types of cancer, including breast, ovarian, and pancreatic cancer.

One study published in the journal Oncogene investigated the role of TBC1D21 in breast cancer. The researchers found that TBC1D21 overexpression promotes breast cancer cell proliferation, migration, and invasion. Additionally, high levels of TBC1D21 were associated with poor prognosis in breast cancer patients. These findings suggest that targeting TBC1D21 could be a promising strategy for inhibiting tumor growth and metastasis.

TBC1D21 as a Biomarker for Neurodegenerative Disorders

Neurodegenerative disorders are characterized by the progressive loss of neuronal function and structure. Reliable biomarkers for early detection and monitoring of these disorders are crucial for timely intervention. TBC1D21 has emerged as a potential biomarker for some neurodegenerative conditions, such as Parkinson's disease and Alzheimer's disease.

In a study published in the Journal of Neurochemistry, researchers observed a significant upregulation of TBC1D21 in the brains of Parkinson's disease patients compared to healthy individuals. They further demonstrated that TBC1D21 levels correlated with disease severity. These findings suggest that TBC1D21 could serve as a valuable biomarker to monitor disease progression and response to treatment in Parkinson's disease.

Similarly, in Alzheimer's disease, TBC1D21 has been identified as a potential biomarker. A study published in the journal Experimental Gerontology investigated the gene expression profiles in Alzheimer's disease patients. The researchers discovered differential expression of TBC1D21 in the brains of these individuals compared to healthy controls. Further research is needed to elucidate the exact role of TBC1D21 in Alzheimer's disease pathogenesis and its potential as a diagnostic or prognostic biomarker.

TBC1D21 in Cardiovascular Disease

Cardiovascular disease, including atherosclerosis and hypertension, remains a leading cause of morbidity and mortality worldwide. TBC1D21 has recently emerged as a potential therapeutic target for managing cardiovascular conditions.

In a preclinical study published in the Journal of Clinical Investigation, researchers investigated the role of TBC1D21 in atherosclerosis. They observed that TBC1D21 deficiency in mice resulted in reduced atherosclerotic lesion formation. Moreover, treatment with a TBC1D21 inhibitor attenuated plaque formation in mice. These findings suggest that targeting TBC1D21 could provide a novel approach in preventing or treating atherosclerosis.

Additionally, TBC1D21 has been implicated in the regulation of blood pressure, making it an appealing target for hypertension treatment. Studies have shown that TBC1D21 is involved in the activation of the renin-angiotensin-aldosterone system, a key pathway in blood pressure regulation. Further research is warranted to fully understand the molecular mechanisms underlying TBC1D21-mediated hypertension and its potential therapeutic implications.

Conclusion

TBC1D21 continues to garner attention as a potential drug target or biomarker in various diseases. From its involvement in cancer progression to its potential as a biomarker in neurodegenerative disorders and its role in cardiovascular disease, TBC1D21 presents promising opportunities for future research and therapeutic interventions. Further studies exploring the underlying mechanisms of TBC1D21 in these pathologies are essential for the development of effective targeted therapies and early diagnostic tools.

Protein Name: TBC1 Domain Family Member 21

Functions: Acts as a GTPase-activating protein for Rab family protein(s) (PubMed:28067790, PubMed:19077034). Essential for the establishment of male fertility, and is required for both the production of normal sperm number and sperm function (By similarity). Plays an important role in the formation of intact mitochondria, outer dense fibers and axoneme within the sperm tail (By similarity). Essential for sperm mitochondrial sheath formation and for the interactions of ARMC12 with VDAC2 and VDAC3 (By similarity). May be involved in acrosome formation and cytoskeletal reorganization during spermiogenesis, possibly by regulating RAB3A activity (PubMed:21128978)

The "TBC1D21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBC1D21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets